Investment analysts at Wedbush issued their Q1 2017 earnings estimates for shares of DexCom in a research note issued to investors on Wednesday. Wedbush analyst Levy.
Category: Oppenheimer Holdings
Brokerages Set Neurocrine Biosciences Inc. (NBIX) Price Target at $66.09
… two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor …